The average number of industry-funded trials started per month was 135.8 before the IRA was passed and 83.6 after — a 38.4% decrease.

A financial toxicity tumor board has effectively reduced financial toxicity for cancer patients, researchers say.

A prognostic index can be used to identify patients with estrogen receptor (ER)-positive, HER2-negative early breast cancer who can safely forgo adjuvant chemotherapy as well as patients who require ...

President Donald Trump’s proposed budget for fiscal year 2026 would reduce the NIH budget by nearly $18 billion.

The FDA has granted fast track designation to INX-315 for the treatment of CCNE1-amplified, platinum-resistant/refractory ovarian cancer.

In an interview, FDA Commissioner Marty Makary opened up about his first weeks on the job and his vision for the future.

Adding penpulimab to chemotherapy can improve progression-free survival for patients with recurrent or metastatic nasopharyngeal carcinoma, data suggest.

Using both liquid and tissue biopsies to guide targeted treatment may improve outcomes in patients with solid tumor malignancies.

In reducing federal funding and downsizing federal health agencies, the Trump administration is impeding cancer research.

Tumor-infiltrating clonal hematopoiesis was associated with a greater risk of recurrence or death in patients with non-small-cell lung cancer.

Induction chemotherapy followed by IMRT is noninferior to CCRT for locoregionally advanced nasopharyngeal carcinoma, data suggest.

Adding perioperative pembrolizumab to standard care can improve EFS in locally advanced head and neck cancer, data suggest.